Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

American Society for Clinical Investigation honors Kaelin

William G. Kaelin, Jr., MDWilliam G. Kaelin, Jr., MD

William G. Kaelin, Jr., MD, of Dana-Farber Cancer Institute, was presented with the 2012 American Society for Clinical Investigation's Stanley J. Korsmeyer Award, in recognition of his contributions to the molecular understanding of cellular oxygen sensing and cellular adaptation to hypoxia. Kaelin was selected as a co-recipient with Gregg L. Semenza, MD, PhD, of Johns Hopkins University School of Medicine.

Kaelin and Semenza's work has defined how this sensing mechanism goes awry in broad spectrum of disorders ranging from the vascular overgrowth associated with many forms of cancer to the reduced vascular density associated with ischemic disease. The Korsmeyer Award also recognizes their success in mentoring future physician-scientists and researchers.

As part of the honor, Kaelin and Semenza shared the $10,000 honorarium and presented the Korsmeyer Lecture at the 2012 American Society for Clinical Investigation/Association of American Physicians Joint Meeting in Chicago on April 29.

Kaelin was recognized for his work that provided a molecular explanation for the hypervascularity of the kidney and brain tumors seen in patients with germline mutations in the von Hippel Lindau (VHL) gene. He showed that VHL-deficient tumor cells produce high levels of hypoxia-inducible gene products, including VEGF, irrespective of oxygen levels.

This work led to a series of key discoveries into how cells sense and respond to changes in oxygen levels. One of the most significant discoveries was that the VHL protein interacts with HIF in an oxygen-sensitive manner and suppresses tumor formation by targeting HIF for degradation.

When a defective VHL-HIF interaction exists due to mutations in VHL, there are increased HIF levels that promote vascular tumor formation. Kaelin’s laboratory also discovered that oxygen-dependent proline hydroxylation of HIFs by a prolyl hydroxylase (PHD2) regulates its ubiquitination by VHL and subsequent degradation. The functional link between these components of the oxygen-sensing network is reflected by the fact that mutations in the genes encoding all three components (PHD2, VHL, or HIF) lead to hereditary polycythemia.

The insights gained from defining the VHL-HIF interaction created a conceptual basis for the successful clinical testing of VEGF inhibitors for metastatic kidney cancer.

Kaelin was elected to the ASCI in 1997 and has received numerous honors for his research, including the Canada Gairdner Award, and is a member of the National Academy of Sciences and the Institute of Medicine.

Kaelin obtained his undergraduate and medical degrees from Duke University. He completed training in Internal Medicine at Johns Hopkins Hospital and was a clinical fellow in Medical Oncology at Dana-Farber. Kaelin is currently professor in the Department of Medicine at Dana-Farber and at Brigham and Women’s Hospital, Harvard Medical School and is a Howard Hughes Medical Institute Investigator.

9/25/2017 2:15:45 AM
  •   Email
  •   Print
  •   Share
  • Media Contacts

    • For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online